DPV 001

Next Previous
Drug Profile

DPV 001

Alternative Names: Autologous DRibble vaccine; Cancer vaccine DRibble; DRibble Vaccine

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UbiVac
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 01 Dec 2017 DPV 001 is still in phase II trials for Non-small cell lung cancer and phase I trials for Prostate cancer in USA (UbiVac pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intralymphatic, Injection)
  • 02 Jun 2017 Efficacy data from a phase II trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top